Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

24 Oct 2018

Abstract excerpt

Abstract DNA sequencing has identified a limited number of driver mutations in metastatic breast cancer beyond single base-pair mutations in the estrogen receptor (ESR1). However, our previous studies and others have observed that structural variants, such as ESR1 fusions, may also play a role. Therefore, we expanded upon these observations by performing a comprehensive and highly sensitive characterization of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Advanced Breast Cancer Therapies
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30355675
DOI: 10.1158/1541-7786.mcr-18-0946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast CancerPMID 30355675Read ↗

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.Semantic proximity Read ↗

The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors.Semantic proximity Read ↗

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).Semantic proximity Read ↗

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Genomic Divergence Between Matched Primary and Metastatic Tumors Across Cancer Types: A Pan-Cancer Analysis of 5,692 SamplesSemantic proximity Read ↗

Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.Semantic proximity Read ↗

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.Semantic proximity Read ↗

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read ↗

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.Semantic proximity Read ↗

Whole genome sequencing of locally advanced and metastatic breast carcinoma unravels relevant molecular signatures and novel events.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.